News

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...
Merck has had a successful track record of beating estimates, having surpassed EPS expectations 88% of the time and beating ...
Merck & Co., Inc. (NYSE:MRK) is one of the top low volatility healthcare stocks to buy now. Analyst Daina Graybosch of ...
Merck is undervalued with strong growth, profitability, and credit strength despite CDMO challenges, offering compelling ...
Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK ...
The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...
In June 2025, the FDA approved KEYTRUDA for perioperative use in adults with resectable, locally advanced head and neck ...
Merck is seeking ways to prepare for a significant upcoming patent cliff. The company has just announced another acquisition ...
Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...
The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...
Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a trial last year, the firm’s cancer drug outperformed the world’s best ...